MiRXES is a privately held life science research tool provider and miRNA diagnostic test developer headquartered in Singapore. MiRXES was founded in 2014 with the vision of creating accurate, affordable and actionable molecular diagnostic tests to improve cancer management.
GrowthMedical BenefitsCorporate Social Responsibility
A multi instutional support
MiRXES is a spin-off from the Bioprocessing Technology Institute of the Agency of Science Technology And Research (A*STAR) and is supported by Exploit Technologies and the National University of Singapore. MiRXES collaborates extensively with academic, clinical and industrial partners locally and globally in advancing the science and business of miRNA.
Harnessing the power of miRNA to transform cancer management :
Advance miRNA technologies to empower translational R & D
Identify novel miRNA disease biomarkers in biofluids and tissues
Develop non-invasive cancer screening and diagnostic tests
Technology for healthcare
MiRXES is looking to revolutionise cancer detection methods by offering blood tests in place of current diagnostic methods to detect early stage cancer. MiRXES develops life science research tools and molecular diagnostic tests or research and clinical diagnostic use. It offers RT-qPCR assays, assay panels, spike-in RNA kits, and biomarker discovery solutions.